GlaucoT Company Profile

Background

Founded in 2019, GlaucoT is a pioneering medical technology company dedicated to developing innovative, non-invasive treatments for glaucoma. The company's mission is to enhance the quality of life for individuals affected by glaucoma by providing safe, effective, and affordable eye care solutions. GlaucoT's flagship product is a wearable device designed to deliver gamma rhythm stimulation, aiming to reduce neuroinflammation without the need for medication or surgical intervention.

Key Strategic Focus

GlaucoT's strategic focus centers on the development and commercialization of its wearable glaucoma treatment device. This device utilizes gamma rhythm entrainment technology to provide neuroprotective therapy, targeting the reduction of neuroinflammation associated with glaucoma. By offering a non-invasive treatment option, GlaucoT aims to address the unmet needs of glaucoma patients seeking alternatives to traditional therapies.

Financials and Funding

GlaucoT has successfully secured funding to support its research and development initiatives. In March 2025, the company received a new investment at a valuation of $6 million. Alesta Elektronik Teknoloji Anonim Şirketi participated in this funding round, increasing its stake in GlaucoT to 11.93%.

Pipeline Development

GlaucoT is actively advancing its wearable glaucoma treatment device through clinical development. A pilot study was initiated to evaluate the short-term efficacy and safety of the device in patients with primary open-angle glaucoma. The study involved daily application of 40 Hz flicker light therapy for one hour over a six-month period, assessing outcomes such as visual field stabilization and adverse event frequency.

Technological Platform and Innovation

GlaucoT's innovation lies in its proprietary wearable device that delivers gamma rhythm stimulation to the visual system. This technology is designed to reduce neuroinflammation and protect retinal ganglion cells, potentially slowing the progression of glaucoma. The device offers a non-invasive, user-friendly treatment option, distinguishing it from existing pharmacological and surgical interventions.

Leadership Team

Veysel Özkapıcı, MSc.EE – CEO/Co-founder: An electronics engineer with a Master's degree from the Technical University of Denmark, Veysel has expertise in micro and nano-electronics. He founded Vidi Medika and BNM Fabrika, developing medical devices such as the "Vidi smart glasses" for amblyopia treatment.

Alperen Acemoğlu, PhD. ME – CTO/Co-founder: Alperen holds a Ph.D. in Bioengineering and Robotics from Istituto Italiano di Tecnologia and Università Degli Studi di Genova. His background includes mechanical and mechatronics engineering, with a focus on developing novel medical technologies.

Abdulkadir Oduncu, MD – CSO/Co-founder: A medical doctor specializing in ophthalmology, Abdulkadir has over 15 years of experience in eye care, particularly in glaucoma and cataract surgeries. He has performed over 20,000 surgical operations and holds several patents in medical technology.

John Marshall, PhD – Chair, Scientific Advisory Board: A renowned medical scientist and inventor, John is the Frost Professor of Ophthalmology at the Institute of Ophthalmology, UCL, and Emeritus Professor at King's College London. He is a pioneer in laser eye surgery.

Leadership Changes

As of the latest available information, there have been no recent significant changes or appointments within GlaucoT's leadership team.

Competitor Profile

Market Insights and Dynamics

The global glaucoma treatment market is experiencing growth due to the increasing prevalence of the disease and advancements in treatment technologies. Non-invasive treatment options are gaining traction, offering patients alternatives to traditional methods.

Competitor Analysis

While specific competitors are not detailed in the available information, companies developing non-invasive glaucoma treatments or wearable medical devices targeting neurodegenerative eye diseases represent potential competition.

Strategic Collaborations and Partnerships

GlaucoT has engaged in strategic collaborations to enhance its market position and innovation capacity. Notably, the company was selected to participate in the EIT Health 2022 Catapult Program, recognizing its business concept and providing access to a network of world-leading companies.

Operational Insights

GlaucoT's non-invasive, wearable device offers a distinct competitive advantage by providing a user-friendly treatment option that does not require medication or surgery. This positions the company favorably in the market, addressing patient preferences for less invasive therapies.

Strategic Opportunities and Future Directions

GlaucoT is poised to expand its market presence by advancing its clinical development programs and pursuing regulatory approvals. The company's innovative approach to glaucoma treatment positions it to capitalize on the growing demand for non-invasive therapeutic options.